1. Home
  2. OCS

as 03-28-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 904.3M IPO Year: N/A
Target Price: $29.50 AVG Volume (30 days): 42.7K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.34 EPS Growth: N/A
52 Week Low/High: $10.55 - $23.08 Next Earning Date: 03-11-2025
Revenue: $757,024 Revenue Growth: -22.31%
Revenue Growth (this year): 927.26% Revenue Growth (next year): 292.79%

OCS Daily Stock ML Predictions

Share on Social Networks: